Good morning :)
$
₹
AbbVie Inc

AbbVie Inc

ABBV

NYSE
Asset Logo

AbbVie Inc

ABBV

NYSE
$261.731.79% (+4.61)
$
₹
$261.731.79% (+4.61)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $454.4B the stock is ranked 26

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

72.42
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

50.45
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$3.55
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.52
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

9.8%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.68%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 28 analysts' reports

Buy
16 analysts
Hold
12 analysts
Sell
0 analyst

Analysts expect a +7.85% price upside over the next year

Current Price$261.73
Target Price$277.31

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Peers

Peers

Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.42
23.42
1Y Return
40.02%
40.02%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
30.09%
30.09%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.03
30.03
1Y Return
32.12%
32.12%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.34
19.34
1Y Return
38.79%
38.79%
Buy Reco %
76.00
76.00
argenx NV ADR
ARGX
argenx NV ADR
P/E Ratio
37.55
37.55
1Y Return
30.88%
30.88%
Buy Reco %
95.45
95.45

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
AbbVie Inc 72.4250.450.52
Amgen Inc23.4217.452.27
Gilead Sciences Inc-15.062.13

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

15.7
0.1
16.6
1.8
15
0.6
16.9
3.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue12.3114.4614.4615.1013.3415.4215.7716.611516.99
Net Income1.361.371.56-0.021.280.930.181.810.693.61
Net Profit Margin11.12%9.47%10.79%-0.14%9.63%6.08%1.17%10.92%4.65%21.26%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. AbbVie Inc (ABBV) share price today is $261.73 as of September 15, 2026 at 1:30 AM IST. The stock touched a day high of $263.67 and a day low of $260.18.

  2. AbbVie Inc stock trades on NYSE under the ticker symbol ABBV.

  3. AbbVie Inc's market capitalization is $454.36B as of September 15, 2026 at 1:30 AM IST.

  4. AbbVie Inc's price-to-earnings (P/E) ratio is 72.42 as of September 14, 2026.

  5. AbbVie Inc's price-to-book (P/B) ratio is 50.45 as of September 14, 2026.

  6. Yes, AbbVie Inc pays a dividend, with a current dividend yield of 2.68%.

  7. Yes, You can buy AbbVie Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy AbbVie Inc shares in three steps: 1. Search AbbVie Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since AbbVie Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in AbbVie Inc (ABBV) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0382 shares at the current price of $261.73.

Loading...